FDA Rejection Triggers Major Stock Selloff and Legal Action
Corcept Therapeutics ($CORT) faces a significant crisis after the FDA issued a Complete Response Letter on December 31, 2025, rejecting its lead drug candidate relacorilant. The regulatory setback, citing insufficient evidence of effectiveness, precipitated a devastating 50.4% stock decline and has now spawned a securities class action lawsuit. Investors who suffered losses exceeding $100,000 have until April 21, 2026 to file lead plaintiff applications, according to legal filings from ClaimsFiler.
The Complete Response Letter represents a major blow to Corcept's clinical pipeline and financial prospects. Rather than approving the drug for commercial use, the FDA determined that the evidence presented did not sufficiently demonstrate relacorilant's therapeutic effectiveness, requiring the company to conduct additional studies or submit more robust clinical data. This outcome effectively halts the company's primary revenue growth catalyst and raises questions about the commercial viability of its broader pipeline strategy.
The Stock Market Reaction and Shareholder Impact
The market's response was swift and severe. Corcept's stock plummeted 50.4% following the FDA announcement, erasing billions in shareholder value and triggering widespread investor losses. This magnitude of decline—representing a fundamental destruction of company valuation—far exceeds typical volatility thresholds and typically warrants securities litigation scrutiny.
The class action lawsuit centers on allegations that the company may have:n
- Misrepresented the strength of relacorilant's clinical trial data
- Failed to adequately disclose regulatory risks to investors
- Provided insufficient transparency regarding development setbacks
- Made statements about drug approval probability that lacked sufficient evidentiary support
Investors with documented losses exceeding $100,000 are being urged to act quickly, as the lead plaintiff filing deadline of April 21, 2026 represents the cutoff for initiating formal legal proceedings. Lead plaintiffs typically become the named representatives in class actions and may recover attorney fees and expenses from any eventual settlement or judgment.
Market Context and Industry Implications
Corcept Therapeutics operates in the specialized pharmaceutical space, focusing on rare endocrine disorders and conditions with limited treatment options. Relacorilant, a selective glucocorticoid receptor modulator, was positioned as a differentiated therapeutic approach for certain conditions where Corcept had built considerable investor expectations.
The FDA's rejection reflects the agency's increasingly rigorous standards for approval, particularly for drugs targeting conditions where alternative treatments exist. The Complete Response Letter—rather than an outright rejection—technically leaves the door open for resubmission if Corcept can address the FDA's specific concerns. However, such regulatory reversals typically require substantial additional clinical work, extended timelines, and significant capital deployment, making rapid reapproval unlikely.
In the broader biotech landscape, FDA rejections and clinical setbacks are not uncommon, but the magnitude of Corcept's stock decline suggests that:
- Relacorilant represented a disproportionate portion of investor hopes for near-term revenue growth
- The market had built elevated expectations into the stock price prior to the FDA decision
- Limited pipeline diversification may have amplified the impact of this single setback
- Investor communications may not have adequately prepared the market for a negative outcome
Investor Implications and Forward Outlook
The securities class action lawsuit creates additional headwinds for Corcept beyond the immediate regulatory setback. Litigation costs, potential settlements, and ongoing legal exposure will strain the company's balance sheet and management attention during a period when strategic pivots are essential.
For shareholders, the situation presents several critical considerations:
- Capital adequacy: Corcept must assess whether its cash reserves remain sufficient to fund continued development, litigation defense, and operations
- Pipeline reassessment: Investors will demand clarity on alternative programs and realistic timelines for potential commercialization
- Management credibility: The magnitude of the stock decline raises questions about pre-announcement guidance and disclosure practices
- M&A vulnerability: The weakened stock price and operational challenges may make Corcept an acquisition target at potentially unfavorable valuations
The April 21, 2026 lead plaintiff deadline serves as a critical juncture for investors to formalize claims. Early-stage securities litigation typically takes years to resolve through settlement or judgment, meaning affected shareholders face extended periods of uncertainty and potential recovery timelines extending into 2027 or beyond.
Corcept Therapeutics now enters a challenging rehabilitation phase. Management must simultaneously navigate FDA regulatory requirements for relacorilant resubmission, defend against securities litigation, stabilize investor confidence, and demonstrate viable near-term revenue opportunities from its existing portfolio. The company's ability to execute on these fronts will determine whether the current crisis represents a temporary setback or a more fundamental erosion of enterprise value.